CD84 CAR T-cell therapy for relapsed/refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using your own immune cells, modified to target a protein called CD84 on leukemia cells. It is for adults with acute myeloid leukemia that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia that has relapsed (come back) or has not responded to at least two rounds of standard treatment.
- Your leukemia cells have a marker called CD84, confirmed by a lab test.
- You are in generally good health, able to perform daily activities without help (ECOG score 0-1), and have adequate organ function.
- You must use effective birth control if you or your partner could become pregnant, and avoid breastfeeding.
- You do not have active infections, severe heart disease, other cancers, or HIV/hepatitis B/C/syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.